Russell Investments Group Ltd. Purchases 109,505 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Russell Investments Group Ltd. increased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 79.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 247,325 shares of the medical device company’s stock after buying an additional 109,505 shares during the period. Russell Investments Group Ltd. owned 0.38% of Tandem Diabetes Care worth $7,316,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Eminence Capital LP lifted its position in Tandem Diabetes Care by 76.1% during the 3rd quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock worth $114,028,000 after acquiring an additional 2,372,458 shares during the last quarter. Paradice Investment Management LLC boosted its stake in Tandem Diabetes Care by 23.9% during the 3rd quarter. Paradice Investment Management LLC now owns 1,520,065 shares of the medical device company’s stock valued at $31,572,000 after purchasing an additional 293,250 shares during the period. Jennison Associates LLC grew its holdings in Tandem Diabetes Care by 14.9% in the 4th quarter. Jennison Associates LLC now owns 1,290,590 shares of the medical device company’s stock valued at $38,176,000 after buying an additional 167,675 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in Tandem Diabetes Care by 0.3% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 793,488 shares of the medical device company’s stock worth $16,481,000 after buying an additional 2,633 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Tandem Diabetes Care by 4.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 367,011 shares of the medical device company’s stock worth $7,623,000 after buying an additional 16,586 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on TNDM shares. Citigroup boosted their target price on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Barclays upped their price objective on shares of Tandem Diabetes Care from $39.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday. Leerink Partnrs raised Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research report on Thursday, April 25th. Stifel Nicolaus upped their price target on Tandem Diabetes Care from $37.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, April 23rd. Finally, StockNews.com raised Tandem Diabetes Care from a “sell” rating to a “hold” rating in a report on Friday, April 19th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $43.80.

Tandem Diabetes Care Stock Performance

Tandem Diabetes Care stock opened at $44.00 on Wednesday. The firm has a market capitalization of $2.84 billion, a P/E ratio of -20.28 and a beta of 1.10. The stock has a fifty day moving average price of $32.91 and a two-hundred day moving average price of $26.53. Tandem Diabetes Care, Inc. has a 52-week low of $13.82 and a 52-week high of $47.00. The company has a debt-to-equity ratio of 1.43, a current ratio of 3.81 and a quick ratio of 3.01.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The firm had revenue of $196.80 million for the quarter, compared to analyst estimates of $204.86 million. Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. As a group, analysts anticipate that Tandem Diabetes Care, Inc. will post -1.62 EPS for the current fiscal year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.